New Jersey Right to Try-Plus Act allows terminally ill patients access to investigational and off-label treatments.

The New Jersey Right to Try-Plus Act permits terminally ill patients to request access to investigational drugs, biological products, and devices that have not been approved by the FDA, as well as off-label treatments using FDA-approved drugs, biological products, and devices. Patients must have a terminal illness, consider all FDA-approved treatment options, receive a prescription from a licensed physician, and provide informed consent.

New Jersey Right to Try-Plus Act allows terminally ill patients access to investigational and off-label treatments.

The New Jersey Right to Try-Plus Act permits terminally ill patients to request access to investigational drugs, biological products, and devices that have not been approved by the FDA, as well as off-label treatments using FDA-approved drugs, biological products, and devices. Patients must have a terminal illness, consider all FDA-approved treatment options, receive a prescription from a licensed physician, and provide informed consent.